Alliance for Regenerative Medicine Announces Agenda for Regen Med Investor Day
- Taking place April 17, 2013 in New York City; Agenda includes keynote talks, focused disease sessions with KOL participation and presentations from 16 top regenerative medicine companies -
WASHINGTON, March 12, 2013 /PRNewswire/ — The Alliance for Regenerative Medicine (ARM) today announced the agenda for its Regen Med Investor Day, the first investor event organized specifically for the regenerative medicine sector. The event will take place on April 17 at the Harmonie Club, 4 East 60(th) Street, New York, NY.
This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry’s leading small- and mid-cap companies as well as exclusive access to regenerative medicine’s top stakeholders.
Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at email@example.com if interested in attending.
7:30am Breakfast & Networking 8:00am Welcome Remarks Keynote Talk - Kieran Murphy, VP, President & CEO, GE Healthcare Life 8:10am Sciences Keynote Talk - Jeff Jonas, President, Shire Regenerative 8:30am Medicine Program Introduction - Jason Kolbert, Senior Biotechnology Analyst, Maxim 8:50am Group 9:00am Clinical Outlooks in Cardiovascular Disease Jason Kolbert, Senior Biotechnology Analyst, Maxim Group (moderator) Douglas Losordo, MD, Adjunct Professor in Medicine-Cardiology, Northwestern University Eduardo Marban, MD, Director, Cedars-Sinai Heart Institute Leslie Miller, MD, Chair, College Of Medicine Dean's Office, University of South Florida 9:55am Break Regenerative Medicine in Wound Healing & Tissue 10:10am Engineering Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray (moderator) Vincent Falanga, MD, Professor, Boston University School of Medicine Will Li, MD, President & Medical Director, The Angiogenesis Foundation Thomas Serena, MD, FACS, CEO and Medical Director SerenaGroup 11:05am Therapeutics for a Broad Range of CNS Diseases Ren Benjamin, Ph.D., Managing Director & Senior Biotechnology Analyst, Burrill & Company (moderator) Sean Savitz, MD, Professor of Neurology, University of Texas Medical School, UTHealth 12:00pm Plated Lunch & Networking Lunchtime Presentation - G. Steven Burrill, CEO, Burrill & 12:45pm Company 1:00pm Cytori Therapeutics - Chris Calhoun, CEO 1:15pm Athersys -Gil Van Bokkelen, Chairman & CEO 1:30pm Mesoblast - Silviu Itescu, CEO & President 1:45pm Juventas Therapeutics - Rahul Aras, President & CEO Aastrom Biosciences - Dan Orlando, Chief Commercial 2:00pm Officer 2:15pm NeoStem -Robin Smith, Chairman & CEO 2:30pm Pluristem Therapeutics - Zami Aberman, Chairman & CEO 2:45pm Cytomedix - Martin Rosendale, CEO 3:00pm Afternoon Break 3:15pm Sangamo BioSciences - Edward Lanphier, President & CEO 3:30pm BioTime Acquisition Corp -Thomas Okarma, President & CEO 3:45pm Advanced Cell Technology (ACT) -Gary Rabin, Chairman & CEO 4:00pm StemCells Inc. - Martin McGlynn, President & CEO 4:15pm Organogenesis - Geoff MacKay, President & CEO 4:30pm Organovo -Keith Murphy, CEO 4:45pm Tigenix -Eduardo Bravo, CEO 5:00pm Mimedx -Michael Senken, CFO Program Wrap-up - Ted Tenthoff, Managing Director & Senior 5:15pm Biotechnology Analyst, Piper Jaffray 5:30pm Networking Reception
This meeting is co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group and in partnership with Life Science Advisors and Blaise Group International.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.
SOURCE Alliance for Regenerative Medicine